Bacterial outer membrane vesicle system for enhancing anti-solid tumor effect of CAR-T (Chimeric Antigen Receptor T) cells as well as preparation method and application of bacterial outer membrane vesicle system
By loading a tumor antigen plasmid onto bacterial outer membrane vesicles expressing aPD-L1 antibody, the problems of tumor microenvironment and antigen heterogeneity in CAR-T therapy for solid tumors were solved, enhancing the targeted recognition and killing ability of CAR-T cells and achieving better anti-solid tumor effects.
Patent Information
- Application Number
- CN202410933587.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-22
AI Technical Summary
Existing CAR-T therapies are not very effective in treating solid tumors, mainly because the suppressive tumor microenvironment and antigenic heterogeneity of solid tumors lead to the obstruction of CAR-T cell infiltration and effector function, and there is also the problem of antigen escape.
Bacterial outer membrane vesicles expressing aPD-L1 antibody were loaded with plasmids encoding tumor antigens. A bacterial outer membrane vesicle system was prepared using genetic engineering technology. By utilizing the targeted delivery capability of bacterial outer membrane vesicles, the plasmids encoding tumor antigens were internalized to the surface of tumor cells, blocking the PD-1/PD-L1 inhibitory signaling axis and improving the tumor microenvironment.
It enhances the targeting recognition and tumor infiltration capabilities of CAR-T cells, solves the problem of antigen heterogeneity, significantly improves the anti-solid tumor effect of CAR-T cells, improves the suppressive tumor microenvironment, and enhances the killing ability of CAR-T cells.
Smart Images

Figure CN118987186A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a bacterial outer membrane vesicle system for enhancing the anti-solid tumor effect of CAR-T cells, and a preparation method and application thereof. Background Art
[0002] Chimeric Antigen Receptor T-cell (CAR-T cell) therapy refers to the use of genetically engineered T cells that can express targeted specific antigens to achieve targeted killing of tumors. Although CAR-T therapy has achieved breakthrough success in the treatment of hematological tumors, its efficacy in patients with a larger number of solid tumors has always been poor. A key challenge is that solid tumors have an inhibitory tumor microenvironment that hinders the infiltration and effector function of CAR-T cells. In addition, due to their inherent antigenic heterogeneity, not all tumor cells express the antigens targeted by CAR. The selection pressure of targeted therapy often leads to problems of antigen loss and antigen escape during treatment, which in turn leads to off-target and drug resistance of CAR-T cells, seriously affecting the survival prognosis of patients.
[0003] In recent years, bacterial outer membrane vesicles containing a large number of components from parent bacteria have been widely used in tumor immunotherapy because they can trigger a strong immune response and play a pro-inflammatory role, improving the inhibitory tumor microenvironment. They cannot replicate in the body, are not contagious, and have better safety than parent bacteria. On the other hand, bacterial outer membrane vesicles, as an attractive emerging cargo transport platform, have been widely used for the delivery of drugs, RNA, plasmids, etc., and can be effectively internalized by tumor cells to achieve genetic modification of tumor tissues. At present, there are no reports on the role of bacterial outer membrane vesicles as a delivery carrier with immunomodulatory activity to overcome the dilemma of CAR-T therapy in solid tumors. Summary of the invention
[0004] The purpose of the present invention is to overcome the defects and shortcomings of the prior art and to provide a bacterial outer membrane vesicle system for enhancing the anti-solid tumor effect of CAR-T cells and a preparation method and application thereof.
[0005] The first technical solution of the present invention is to provide a bacterial outer membrane vesicle system for enhancing the anti-solid tumor effect of CAR-T cells, which is composed of bacterial outer membrane vesicles that can express aPD-L1 antibodies on the surface and are loaded with plasmids encoding tumor antigens.
[0006] Preferably, the bacterial outer membrane vesicles are derived from, but not limited to, Escherichia coli, Vibrio cholerae, Shigella flexneri, etc. Further preferably, the Escherichia coli may be a W3110, DH5α, or BL21 strain.
[0007] Preferably, the encoded tumor antigens include but are not limited to the extracellular segment of HER2 antigen (HER2 ECD), and other target antigens of solid tumor CAR-T cells.
[0008] Preferably, the average particle size of the bacterial outer membrane vesicles is 78.7 nm to 122.4 nm.
[0009] The second technical solution of the present invention is to provide a method for preparing a bacterial outer membrane vesicle system for enhancing the anti-solid tumor effect of CAR-T cells, comprising the following steps:
[0010] S1. Clone the gene sequence expressing bacterial hemolysin protein ClyA into pET28a(+) plasmid;
[0011] S2. Cloning the gene sequence capable of expressing the aPD-L1 antibody into the pET28a(+) plasmid containing the ClyA gene sequence to obtain a plasmid containing the gene sequence expressing the aPD-L1 antibody;
[0012] S3, transforming the plasmid obtained in step S2 into the target bacteria to establish a bacterial strain stably expressing the aPD-L1 antibody;
[0013] S4, collecting the bacterial strain obtained in step S3, adding isopropyl-β-D-thiogalactoside (IPTG) to induce protein expression, and filtering to obtain bacterial outer membrane vesicles expressing aPD-L1 antibody by gradient centrifugation;
[0014] S5. Loading the plasmid encoding the tumor antigen into the bacterial outer membrane vesicles obtained in step S4 to obtain the system.
[0015] Preferably, in step S5, the loading of the plasmid encoding the tumor antigen is performed by electroporation.
[0016] In a specific embodiment of the present invention, aPD-L1 antibody is first expressed on bacteria using genetic engineering technology, and then the bacterial outer membrane vesicles expressing aPD-L1 antibody are obtained by gradient centrifugation and filtration, which have the effect of targeting PD-L1 protein on the tumor surface and blocking PD-1 / PD-L1 inhibitory signals, and then the plasmid encoding HER2 ECD is loaded into the bacterial outer membrane vesicles by electroporation. On the one hand, HER2 ECD can be modified as an antigen to the surface of tumor cells to solve the problem of antigen heterogeneity widely existing in solid tumors, and on the other hand, the bacterial outer membrane vesicles can effectively improve the inhibitory tumor microenvironment and significantly enhance the anti-tumor immune efficacy mediated by CAR-T cells. The functionalized bacterial outer membrane vesicles are expected to become a new supporting drug for CAR-T therapy, providing a new option for enhancing CAR-T treatment of solid tumors.
[0017] The third technical solution of the present invention is to provide the use of the above-mentioned bacterial outer membrane vesicle system in the preparation of a pharmaceutical preparation for enhancing the anti-solid tumor effect of CAR-T cells, which can better enhance the anti-solid tumor effect of CAR-T cells.
[0018] Preferably, the solid tumors include breast cancer and liver cancer.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] (1) The present invention can actively target tumor tissues and block the PD-1 / PD-L1 inhibitory signaling axis by expressing aPD-L1 antibodies on bacterial outer membrane vesicles, thereby avoiding premature exhaustion of CAR-T cells.
[0021] (2) The present invention loads the plasmid encoding HER2 ECD into bacterial outer membrane vesicles, and utilizes the targeted delivery effect of bacterial outer membrane vesicles to internalize the plasmid into tumor cells, thereby modifying the antigen to the cell surface, thereby solving the antigen-negative problem caused during the treatment of solid tumors.
[0022] (3) The present invention can induce a strong immune response through the bacterial outer membrane vesicles themselves, improve the characteristics of the inhibitory tumor microenvironment, and enhance the infiltration and effector function of CAR-T cells.
[0023] (4) Since the present invention uses genetically reprogrammed bacterial outer membrane vesicles to load plasmids encoding and expressing HER2 ECD, it can effectively modify the antigen to the surface of tumor cells, thereby improving the targeted recognition ability of CAR-T cells to tumors; at the same time, bacterial outer membrane vesicles can effectively improve the inhibitory tumor microenvironment, increase the infiltration and activation killing ability of CAR-T cells in the tumor, and better enhance the anti-solid tumor effect of CAR-T cells.
[0024] (5) The platform technology provided by the present invention is universal and provides a new option for enhancing CAR-T therapy for solid tumors, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1Preparation and characterization of POMVs expressing aPD-L1 antibody; a. Molecular sequence design of bacterial outer membrane vesicles (POMVs) expressing aPD-L1 scFv; b. Western blot detection of aPD-L1 antibody expression on POMVs; c. After POMVs were coupled to latex beads, the expression of aPD-L1 antibody was detected by flow cytometry; d. The morphology of POMVs was detected by electron microscopy; scale bar: 100 nm; e. The particle size distribution of POMVs was detected by NTA; f. Biochemical indices of mouse serum after POMV injection; g. H&E staining of major organs of mice after POMV injection.
[0026] Figure 2 Analysis of the targeting ability of POMV to 4T1 tumor cells in vivo and in vitro; a. Confocal microscopy was used to observe the targeting ability of POMV to 4T1 tumor cells; b. Flow cytometry was used to count the binding level of POMV; c. DiI (red) was used to label OMV and POMV, DiO (green) was used to label the 4T1 breast cancer cell membrane, DAPI (blue) was used for nucleus staining, and the binding of vesicles to tumor cells was observed under confocal microscopy after aPD-L1 was blocked in advance; Scale bar: 10μm; d. Intravenous injection of OMV and POM Representative in vivo imaging of mice after V; tumor markers are shown in the left schematic; e. Confocal microscopy images of tumor tissue sections 24 hours after intravenous injection of DiR-labeled OMVs and POMVs, with DAPI (blue) used for nuclei staining; Scale bar: 50 μm; f. Representative fluorescence images of heart (H), lung (Lu), liver (Li), spleen (S), kidney (K), intestinal tissue (I) and tumor tissue (T) collected at different time points after intravenous injection of DiR-labeled OMVs and POMVs, as well as statistical analysis of fluorescence signals in tumor tissues.
[0027] Figure 3 The effect of POMV on the suppressive tumor microenvironment and T cell-mediated anti-tumor immune response; af. The MDSCs cells, Treg cells, M2, M1 macrophages, CD8 + T and IFN-γ + CD8 + Representative flow cytometry plots and statistical results of T cells (n=3); one-way ANOVA and Tukey post hoc test, *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001, ns: not significant.
[0028] Figure 4The effect of antigen modification mediated by the BROAD-CAR system on CAR-T cells in vitro; a. Schematic diagram of the BROAD-CAR platform; b. Fluorescence microscopy showing the expression of HER2 on the surface of 4T1 cells at different time points and statistical results, scale: 100μm; c. CAR-T cell activation after co-incubation of tumor cells with different treatments with CAR-T cells; d. The proportion of effector memory cells in CAR-T cells after co-incubation of tumor cells with different treatments with CAR-T cells; e. Representative flow cytometry of CAR-T cells that can secrete effector cytokines after co-incubation of tumor cells with different treatments with CAR-T cells; f. After tumor cells were treated with different concentrations of BROAD-CAR, CAR-T cells killed tumor cells; g. The effect of different vesicle treatments and different effector-target ratios on CAR-T cell killing of tumors; *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001, ns: not significant.
[0029] Figure 5 Analysis of the therapeutic effect of the BROAD-CAR system in heterogeneous tumors; a. Treatment of tumor-bearing BALB / c mice; 60 days after tumor inoculation, tumor-rejecting mice were re-challenged with 4T1 and 4T1-HER2 tumor cells; bc. Average tumor trajectory and survival curve of mice with 4T1 / 4T1-HER2 orthotopic tumors after different treatments (n=6); d. Representative bioluminescence imaging of BALB / c mice inoculated with 4T1-HER2 tumor cells after combined treatment and subjected to various recurrence challenges, with untransplanted tumor-bearing mice as controls; e. Measurement of 4T1 / 4T1-HER2 tumor volume in re-challenged mice and naive mice; f. In vivo bioluminescence imaging tracking tumor metastasis and proliferation after intravenous injection of heterogeneous 4T1 tumor cells with different treatments (n=6); g. Lung gross specimens and metastatic nodule counts after different treatments (n=6); hi. Activated CAR infiltrating in tumor tissues + Representative FCM images and frequencies of T cells (n=3); jk. Representative FCM images and frequencies of Ki-67-positive CAR-T cells infiltrating in tumor tissues (n=3); *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001, ns: not significant.
[0030] Figure 6Effects of BROAD-CAR system on antigen-negative liver cancer; a. Schematic diagram of BROAD-CAR-T therapy in orthotopic Hepa1-6 tumor-bearing mice; b. Bioluminescence imaging of Hepa1-6 orthotopic tumor mice after different treatments (n=6); c. Fold change of average bioluminescence of tumors after different treatments (n=6); d. Digital photos of liver after different treatments (n=6), scale bar, 2 cm; e. Liver HE sections after different treatments (n=6), scale bar is 1000μm; f. Survival curve; g.-h. CD3 + CD8 + (g) and CAR + (h) percentage (n=3); il. intracellular cytokine levels in CAR-T cells [including TNF-α (i), perforin (j), GZMB (k) and IFN-γ (l)] (n=3); m. expression level of HER-2 antigen in different organs and tissues; *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001, ns: not significant. DETAILED DESCRIPTION
[0031] The specific embodiments of the present invention below will provide a detailed and comprehensive description of the technical solutions of the present invention. It should be noted that the embodiments provided represent only a part of the present invention, not all of it. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Unless otherwise specified, the experimental methods used in the examples of the present invention are all conventional methods; the materials, reagents, etc. used are reagents and materials that can be obtained from commercial channels unless otherwise specified.
[0033] The basic principle of the present invention is as follows Figure 1 As shown in a, the present invention is used to enhance the anti-solid tumor effect of CAR-T cells by loading a plasmid encoding an antigen on the bacterial outer membrane vesicles expressing the aPD-L1 antibody.
[0034] First, the pET28a-ClyA plasmid was constructed, and then the sequence encoding the myc tag and the aPD-L1 antibody protein scFv segment was fused to the C-terminus of the bacterial hemolysin protein ClyA sequence. Subsequently, the expression plasmid was transferred into the W3110 strain to obtain an engineered strain expressing the ClyA-aPD-L1 scFv-myc chimeric protein in the outer membrane; further, after adding IPTG to induce protein expression, the bacterial outer membrane vesicles expressing the aPD-L1 antibody were obtained by gradient centrifugation and filtration. The plasmid encoding HER2 ECD was loaded into the prepared bacterial outer membrane vesicles by electroporation.
[0035] Since these bacterial outer membrane vesicles express aPD-L1 antibodies that can bind to tumors on their surface, on the one hand, the targeted delivery of plasmids encoding antigens solves the problem of antigen heterogeneity that is widely present in solid tumors. On the other hand, bacterial outer membrane vesicles enhance the effect of CAR-T in treating solid tumors by reshaping the tumor inhibitory microenvironment.
[0036] Example 1 Construction and characterization of POMVs stably expressing aPD-L1 scFv
[0037] In this example, the Escherichia coli W3110 strain with msbB gene mutation was used as the parent strain to produce bacterial outer membrane vesicles. First, the pET28a-ClyA plasmid was constructed, and then the sequence encoding the myc tag and aPD-L1 scFv was fused to the C-terminus of the bacterial hemolysin protein ClyA sequence. Subsequently, the expression plasmid was transferred into the W3110 strain to obtain an engineered strain expressing the ClyA-aPD-L1scFv-myc chimeric protein in the outer membrane ( Figure 1 a). The expression of the target protein was induced by adding isopropyl-β-D-thiogalactoside (IPTG). After multiple steps of centrifugation and filtration, bacterial outer membrane vesicles (POMVs) stably expressing aPD-L1 scFv were obtained.
[0038] The specific construction process includes the following steps:
[0039] 1. Construction of pET28a-ClyA-aPD-L1 scFv-myc plasmid
[0040] (1) The ClyA gene sequence was amplified from Escherichia coli W3110 and inserted between the BamHI and EcoRI restriction sites of pET28a to obtain the pET28a-ClyA plasmid;
[0041] (2) aPD-L1 scFv (US11174316B2) sequence was synthesized by BGI, amplified by PCR, and a (G4S)3 linker peptide was added to the N-terminus of the sequence and a myc tag was added to the C-terminus;
[0042] (3) Insert the sequence in step (2) between the EcoRI and HindⅢ restriction sites of the pET28a-ClyA plasmid to obtain the pET28a-ClyA-aPD-L1 scFv-myc plasmid.
[0043] 2. Preparation of bacterial outer membrane vesicles (POMVs) expressing aPD-L1 scFv
[0044] (1) Take 50 μL of Escherichia coli W3110 strain and place it in a centrifuge tube and melt it on an ice bath;
[0045] (2) Add the pET28a-ClyA-aPD-L1 scFv-myc plasmid constructed in the above step, mix gently, and continue to place in the ice bath for 20 minutes;
[0046] (3) Place the centrifuge tube in a 42°C water bath for 45 seconds, then quickly transfer to an ice bath and let stand for 2 minutes;
[0047] (4) Add 500 μL of LB liquid medium without antibiotics;
[0048] (5) Incubate at 37°C in a shaker at 200 rpm for 1 hour;
[0049] (6) Absorb the bacterial solution and apply it to LB solid medium containing kanamycin;
[0050] (7) Incubate in a 37°C incubator overnight;
[0051] (8) Picking a single clone colony and culturing it in LB liquid culture medium to obtain a bacterial strain expressing aPD-L1 scFv;
[0052] (9) inoculating the bacterial strain obtained above into LB liquid medium and culturing at 37° C. until the logarithmic growth phase;
[0053] (10) When the OD value reached 0.5-0.6, IPTG was added to the culture medium to induce protein expression;
[0054] (11) Centrifuge at 5,000 g for 30 min at 4°C to remove bacteria and collect the supernatant;
[0055] (12) OMVs were filtered using a 0.45 μm polyvinylidene fluoride filter and concentrated using a 50 kDa ultrafiltration membrane;
[0056] (13) filtering the concentrate using a 0.22 μm polyethersulfone filter;
[0057] (14) ultracentrifugation at 150,000 g for 3 h at 4°C;
[0058] (15) The precipitate was resuspended in PBS (pH 7.4) to obtain bacterial outer membrane vesicles expressing aPD-L1 scFv.
[0059] The expression of aPD-L1 scFv in engineered E. coli-derived POMVs was verified by Western blot and flow cytometry analysis. Figure 1 bc). Characterization by transmission electron microscopy and NTA revealed that POMVs were dispersed and closed spheres with uniform morphology and an average particle size of 78.7nm to 122.4nm ( Figure 1de). In addition, we injected POMV, OMV or an equal volume of PBS into mice through the tail vein at a concentration of 2.5 mg / kg on days 7, 9, and 11, respectively, and collected blood from the eyeballs on day 13 to analyze alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), urea nitrogen (BUN) and creatinine (CRE). The mice were killed and the main organs (heart, liver, spleen, lungs and kidneys) were collected and fixed in 4% paraformaldehyde overnight. The fixed tissues were then embedded and sectioned, and stained with hematoxylin-eosin (H&E) to assess tissue damage. Serum biochemistry and H&E staining results showed that the bacterial outer membrane vesicles expressing aPD-L1 scFv had good biosafety ( Figure 1 fg).
[0060] Example 2 Analysis of tumor targeting of POMV in vivo and in vitro
[0061] 4T1 cells were cultured at 1×10 5 The cells were cultured in 35 mm confocal microscopy dishes at a density of 100 μg / mL for 12 hours. The tumor cells were then stained with DiO dye and washed with PBS to remove free dye. They were then incubated with DiI-labeled POMV or OMV for 2 hours and washed three times with PBS to remove unbound vesicles. The nuclei were stained with DAPI and the binding of 4T1 to POMV was observed using a confocal microscope. The results showed that POMV had better targeting binding ability to 4T1 tumor cells than OMV ( Figure 2 a).
[0062] Flow cytometry was further used to analyze the blocking effect of POMV on PD-L1 on tumor cells. 4T1 cells were inoculated in a cell culture dish, and when the cell confluence reached 70%-80%, POMV, OMV or an equal volume of PBS was added and incubated at 37°C for 2 hours. Unbound vesicles were washed three times with PBS to remove the cells, and the cells were incubated with anti-PD-L1 antibodies for 30 minutes before analysis using a flow cytometer. Flow cytometry analysis showed that POMVs significantly reduced the expression of PD-L1 on the tumor surface, while no significant changes were observed in the OMV group and PBS group ( Figure 2 b). After we added PD-L1 antibody (20 μg / mL) to pre-block PD-L1 on the surface of tumor cells before co-incubation with POMV, confocal microscopy and flow cytometry showed that the binding of POMV to 4T1 cells was significantly reduced ( Figure 2 c), which indicates that the binding of POMV to tumor cells is due to the direct interaction between aPD-L1 scFv and PD-L1 protein on the surface of tumor cells.
[0063] Then, using 5×10 54T1 cells were injected into the mammary fat pad to establish a 4T1 orthotopic breast cancer model to verify the targeting of POMV to tumor tissue in vivo. DiR dye-labeled vesicles were injected into mice via the tail vein. IVIS fluorescence imaging showed that both OMV and POMV had significant accumulation in tumor tissue, but POMV had better targeting to tumor tissue ( Figure 2 d). We took tumor tissue sections to further analyze the infiltration of DiR-labeled vesicles in the tumor and also found that POMV had significant accumulation in the tumor tissue ( Figure 2 e). Next, we investigated the distribution of vesicles in tumor tissues at different time points and found that POMVs accumulated more significantly in tumor tissues than OMVs, and the fluorescence of tumor tissues was strongest at 24 h ( Figure 2 f). This indicates that the modification of aPD-L1 scFv can significantly increase the targeting of OMV to tumor tissues, laying the foundation for its effective biological function in vivo.
[0064] Example 3 Effects of POMV on the suppressive tumor microenvironment and T cell-mediated anti-tumor immune response
[0065] 5×10 5 4T1 cells were injected into the mammary fat pad to establish a 4T1 orthotopic breast cancer model. POMV, OMV or an equal volume of PBS were injected into the mice through the tail vein at a concentration of 2.5 mg / kg on days 7, 9, and 11. The mice were killed on day 13 and the tumor tissues were taken for flow cytometry analysis. We found that compared with the control group, POMV significantly reduced the proportion of Treg cells, MDSCs cells and M2 macrophages in tumor tissues ( Figure 3 ad). POMV increased the proportion of M1 macrophages that recruited effector T cells and significantly improved the endogenous effector CD8 + The infiltration of T cells and the significant increase in IFN-γ + CD8 + T cells, enhancing the anti-tumor effect of effector T cells ( Figure 3 df). These results indicate that POMV can effectively improve the suppressive tumor microenvironment and significantly enhance T cell-mediated anti-tumor immunity, indicating that it has great application potential in CAR-T therapy.
[0066] Example 4 Effect of antigen modification mediated by BROAD-CAR system in vitro on CAR-T cells
[0067] In order to further address the problem of heterogeneity in tumor antigen expression, this example constructs a BROAD-CAR system based on POMV. By utilizing the loading and targeted delivery capabilities of bacterial outer membrane vesicles, a plasmid expressing exogenous CAR target antigens is first designed. The pEGFP-N1-CD8sp-HER2 ECD-CD8hinge-CD8TM plasmid expressing the extracellular segment sequence of the HER2 antigen is loaded into POMV by electroporation. After being internalized and absorbed by tumor cells, it can achieve stable antigen expression on the tumor surface, and then effectively activate CAR-T cells to achieve specific killing of tumor cells ( Figure 4 a).
[0068] The specific construction process includes:
[0069] 1. Construction of pEGFP-N1-CD8sp-HER2 ECD-CD8hinge-CD8TM plasmid
[0070] (1) HER2 ECD sequence (US006333169B1) was synthesized by BGI;
[0071] (2) using in-fusion cloning technology to synthesize the various parts of CD8sp-HER2 ECD-CD8hinge-CD8TM;
[0072] (3) Insert the sequence in step (2) between the HindⅢ and XmaI restriction sites of the pEGFP-N1 plasmid to obtain the pEGFP-N1-CD8sp-HER2 ECD-CD8hinge-CD8TM plasmid.
[0073] 2. Preparation of BROAD-CAR or OMV@H
[0074] (1) Place the electroporation cuvette on ice;
[0075] (2) Label the sample tubes;
[0076] (3) Resuspend POMV or OMV and the plasmid constructed in step 1 in CytoMix buffer to a final volume of 200 μL;
[0077] (4) Mix the two and transfer them to an electroporation cuvette, and set the electroporation parameters to 400Ω, 350V, and 125μF for electroporation;
[0078] (5) After electroporation, the mixture was immediately aspirated and diluted with 10 ml of PBS;
[0079] (6) Ultracentrifugation at 100,000 g for 70 min at 4°C to obtain BROAD-CAR or OMV@H;
[0080] The authors investigated whether POMV can effectively express the loaded plasmid on the surface of tumor cells. The expression vector carries a GFP fluorescent reporter gene, and the expression level of HER2 antigen on the surface of tumor cells treated with this system can be evaluated by fluorescence confocal microscopy and flow cytometry. 5 The cells were cultured in a 35 mm confocal microscopy dish for 12 hours. BROAD-CAR or OMV@H was then added and incubated for 2 hours. Unbound vesicles were washed three times with PBS to remove them. Confocal microscopy was then used to observe the modification of 4T1 tumor surface antigens. The results showed that POMVs were able to effectively internalize HER2 into tumor cells and successfully express HER2 antigen protein on the surface of 4T1 tumor cells ( Figure 4 b). Flow cytometry was further used to analyze the modification of tumor antigens. 4T1 cells were inoculated in a cell culture dish. When the cell confluence reached 70%-80%, BROAD-CAR or OMV@H was added and incubated with CAR-T cells for 24 hours. Unbound vesicles were washed three times with PBS to remove them. CAR-T activation markers CD69 and CD107, CAR-T effector and memory phenotype changes, and the proportion of CAR-T cells secreting IFN-γ and TNF-α were analyzed by flow cytometry. It was found that CD107 and CD69 associated with T cell activation were significantly upregulated in CAR-T cells, and the proportion of effector memory T cells and the proportion of effector CAR-T cells secreting IFN-γ and TNF-α were significantly increased, while these molecules in the control group remained basically unchanged, indicating that the system successfully modified tumor antigens to the surface of tumor cells and enhanced the effect of CAR-T cells on antigen-negative tumors in an antigen-specific manner ( Figure 4 In addition, by comparing different BROAD-CAR co-incubation doses or changing the ratio of tumor cells to effector cells, we found that the CAR-T cell killing effect mediated by the BROAD-CAR system was dose-dependent. Even at a concentration as low as 0.02 μg / mL, its cytotoxicity to tumor cells was still observed ( Figure 4 f). BROAD-CAR can also drive CAR-T cells to lyse target cells at different effector-target ratios such as high E:T ratio and low E:T ratio ( Figure 4 g).
[0081] Example 5 Analysis of the in vivo anti-tumor effect of the BROAD-CAR-T platform
[0082] In view of the potential of the BROAD-CAR platform to reverse the suppressive immune microenvironment and decorate antigens, this example first established an antigen-heterogeneous 4T1 subcutaneous breast cancer model to evaluate the synergistic effect of BROAD-CAR with CAR-T cells in vivo ( Figure 5a).
[0083] The specific establishment process includes:
[0084] 1. Construction of HER2 antigen-positive 4T1 cell line
[0085] (1) The HER2 (NM_001003817.1) sequence was synthesized by BGI and subcloned into the plasmid pCDH-CMV-MCS-EF1-copGFP;
[0086] (2) HEK 293T cells were cultured at 2×10 6 The cells were inoculated into the culture dish at a density of 100 μg / mL and the subsequent experiments were continued when the cells were 60% confluent;
[0087] (3) Prepare a mixture of three transfection plasmids: 20 μg of the target plasmid, 15 μg of psPAX2 plasmid, and 5 μg of pMD2.G plasmid are added to 1 ml of OptiMEM medium;
[0088] (4) Add 120 μl of PEI reagent to 1 ml of OptiMEM medium;
[0089] (5) Carefully add the transfection mixture to HEK 293T cells;
[0090] (6) At 18 h after transfection, the HEK 293T supernatant containing the transfection reagent was replaced with DMEM complete medium;
[0091] (7) About 40 hours after transfection, the culture medium containing lentivirus was harvested and centrifuged at 500 g to remove impurities. The supernatant was passed through a 45 μm polyethersulfone filter and transferred to a sterile storage tube.
[0092] (8) 1×10 5 4T1 cells were seeded into 6-well culture dishes at a density of;
[0093] (9) Incubate the cells overnight;
[0094] (10) Prepare lentiviral dilutions in DMEM containing 4 μg / mL polybrene;
[0095] (11) Gently aspirate the culture medium from the cells;
[0096] (12) Add 2 mL of virus dilution to each well;
[0097] (13) After culturing for 24 h, replace the culture medium with fresh one and select the target cells using puromycin;
[0098] (14) An inverted fluorescence microscope was used to observe the expression of GFP fluorescence in the stably transfected 4T1 cell line overexpressing HER2 antigen.
[0099] 2. Construction of Antigen Heterogeneous 4T1 Subcutaneous Breast Cancer Model
[0100] (1) Mixing the HER2-overexpressing 4T1 cells obtained in the previous step with wild-type 4T1 cells at a ratio of 1:1;
[0101] (2) According to 5×10 5 The cells were injected subcutaneously into mice.
[0102] POMV or BROAD-CAR was administered at a concentration of 2.5 mg / kg on days 7 and 12, and 5 × 10 6 The CAR-T cells were injected into mice via the tail vein. The results showed that compared with the recurrence caused by the simple use of POMV combined with CAR-T, the BROAD-CAR T system almost completely eliminated the antigen-heterogeneous tumors ( Figure 5 b) and greatly improved the survival time of mice ( Figure 5 c). To further explore whether our treatment can induce long-term immune memory response in solid tumors, we re-challenged mice that were completely cured after treatment with the BROAD-CAR T system. At 60 days, after re-inoculation with 4T1 and 4T1-HER2 tumor cells, we found that mice had strong tumor rejection regardless of whether HER2 antigen was expressed. This may be due to the epitope diffusion of antigens in mice treated with the combination group, which not only produced antigen-specific immune memory response, but also produced effective immune memory response to 4T1 tumor cells that do not express HER2 ( Figure 5 de). Tumor recurrence and metastasis are the main factors affecting patient prognosis. To further confirm the effectiveness of BROAD-CAR system in enhancing CAR-T therapy, we then used immune-competent BALB / c mice to inoculate heterogeneous 4T1 tumor cells through the tail vein to construct a lung metastasis model. After different treatments, we found that the BROAD-CAR T system significantly reduced the bioluminescence of the tumor in the lungs and significantly reduced the number of metastases ( Figure 5 fg). Further analysis of tumor tissues revealed that during the treatment with the BROAD-CAR T system, due to the stimulation of the HER2 ECD antigen decorated on the tumor surface, the expression level of CD69 on the surface of CAR-T cells increased, indicating that there was significantly more activated CAR-T cell infiltration ( Figure 5 hi). In addition, endogenous T cells with effector function also increased significantly ( Figure 5jk). These findings suggest that the BROAD-CAR T system not only regulates the activation of CAR-T cells by decorating heterogeneous tumor cells with antigens, but also simultaneously utilizes the immunomodulatory capacity of POMV itself to enhance the effector function of CAR-T cells and endogenous immune response.
[0103] Example 6 Analysis of the therapeutic effect of the BROAD-CAR system on antigen-negative liver cancer
[0104] Given that the BROAD-CAR platform has shown efficacy in enhancing the CAR-T effect in an antigen-heterogeneous breast cancer model, this example further validates this therapeutic effect using an orthotopic liver cancer model ( Figure 6 a).
[0105] 1×10 6 Hepa1-6 cells were resuspended in 25 μL DMEM / Matrigel gel mixture. After anesthesia, an 8 mm midline incision was made in the upper abdomen of the mouse to expose the left lobe of the liver, and Hepa1-6 cells were inoculated in situ into the left lobe of the liver using a microinjector. POMV or BROAD-CAR was inoculated at a concentration of 2.5 mg / kg on days 7, 9, and 11, and 5×10 6 The CAR-T cells were injected into mice via the tail vein. After BROAD-CAR-T treatment, the bioluminescent signal was almost undetectable in the liver tumors ( Figure 6 bc). Gross imaging and H&E staining of liver tissue showed that the tumors in the BROAD-CAR-T group almost completely disappeared ( Figure 6 de), and the mice had the longest survival time ( Figure 6 f). Tumor tissues after different treatments were collected for further analysis. Even in the HER2 antigen-negative HCC model, the BROAD-CAR platform significantly increased endogenous CD8 + The frequency of T cells ( Figure 6 g). In addition, the platform enhanced the infiltration and function of CAR-T cells in tumor tissues and significantly increased the proportion of CAR-T cells secreting TNF-α, perforin, GZMB, and IFN-γ ( Figure 6 hl). In addition, flow cytometry analysis of HER2 antigen expression in different tissues showed that the BROAD-CAR platform can specifically target liver cancer tissue and perform HER2 antigen modification ( Figure 6 m).
[0106] Obviously, the above embodiments of the present invention are only examples for clearly illustrating the technical solution of the present invention, and are not intended to limit the specific implementation methods of the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the claims of the present invention shall be included in the protection scope of the claims of the present invention.
Claims
1. A bacterial outer membrane vesicle system for enhancing the anti-solid tumor effect of CAR-T cells, characterized in that: It is composed of bacterial outer membrane vesicles that express aPD-L1 antibodies on the surface and are loaded with plasmids encoding tumor antigens.
2. The bacterial outer membrane vesicle system according to claim 1, characterized in that The sources of bacterial outer membrane vesicles include Escherichia coli, Vibrio cholerae, and Shigella flexneri.
3. The bacterial outer membrane vesicle system according to claim 1, characterized in that The Escherichia coli include W3110, DH5α and BL21 strains.
4. The bacterial outer membrane vesicle system according to claim 1, characterized in that The encoded tumor antigen includes HER2 ECD.
5. The bacterial outer membrane vesicle system according to claim 1, characterized in that The average particle size of the bacterial outer membrane vesicles is 78.7nm to 122.4nm.
6. The method for preparing the bacterial outer membrane vesicle system according to any one of claims 1 to 5, characterized in that: The following steps are involved: S1. Clone the gene sequence of bacterial hemolysin protein ClyA into pET28a(+) plasmid; S2, cloning the gene sequence capable of expressing the aPD-L1 antibody into the pET28a(+) plasmid containing the ClyA gene sequence obtained in step S1 to obtain a plasmid containing the gene sequence expressing the aPD-L1 antibody; S3, transforming the plasmid obtained in step S2 into the target bacteria to establish a bacterial strain that stably expresses the aPD-L1 antibody; S4, collecting the bacterial strain obtained in step S3, adding isopropyl-β-D-thiogalactoside to induce protein expression, performing gradient centrifugation, and filtering to obtain bacterial outer membrane vesicles expressing aPD-L1 antibody; S5. Loading the plasmid encoding the tumor antigen into the bacterial outer membrane vesicles obtained in step S4 to obtain the system.
7. The preparation method according to claim 6, characterized in that: The load in step S5 is electroporated.
8. Use of the bacterial outer membrane vesicle system according to claim 1 in the preparation of a pharmaceutical preparation for enhancing the anti-solid tumor effect of CAR-T cells.
9. The use according to claim 8, characterized in that: The solid tumors include breast cancer and liver cancer.
Citation Information
Cited By
Bacterial outer membrane vesicle presenting Stoppin peptide as well as construction method and application of bacterial outer membrane vesicle
CN121059841A
